Sartorius Stedim Biotech SA Net Assets
Sartorius Stedim Biotech SA net assets. Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has net assets worth €4.25 Billion EUR (≈ $4.97 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.92 Billion ≈ $9.26 Billion USD) and total liabilities (€3.67 Billion ≈ $4.29 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Sartorius Stedim Biotech SA net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.25 Billion |
| % of Total Assets | 53.64% |
| Annual Growth Rate | 18.09% |
| 5-Year Change | 138.06% |
| 10-Year Change | 440.38% |
| Growth Volatility | 25.32 |
Net Assets of Sartorius Stedim Biotech SA (2005–2025)
Net assets of Sartorius Stedim Biotech SA from 2005 to 2025. This chart illustrates how Sartorius Stedim Biotech SA's net assets have evolved over time, based on quarterly financial data. Also explore Sartorius Stedim Biotech SA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Sartorius Stedim Biotech SA (2005–2025)
The table below shows the annual net assets of Sartorius Stedim Biotech SA from 2005 to 2025. For live market cap and overall valuation, see market cap of Sartorius Stedim Biotech SA.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
+2.54% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
+50.52% |
| 2023-12-31 | €2.67 Billion ≈ $3.13 Billion |
+6.32% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
+45.06% |
| 2021-12-31 | €1.73 Billion ≈ $2.03 Billion |
+16.88% |
| 2020-12-31 | €1.48 Billion ≈ $1.73 Billion |
+25.92% |
| 2019-12-31 | €1.18 Billion ≈ $1.38 Billion |
+12.71% |
| 2018-12-31 | €1.04 Billion ≈ $1.22 Billion |
+18.81% |
| 2017-12-31 | €879.45 Million ≈ $1.03 Billion |
+15.18% |
| 2016-12-31 | €763.56 Million ≈ $892.68 Million |
+17.97% |
| 2015-12-31 | €647.22 Million ≈ $756.67 Million |
+20.19% |
| 2014-12-31 | €538.51 Million ≈ $629.58 Million |
+11.76% |
| 2013-12-31 | €481.84 Million ≈ $563.32 Million |
+10.84% |
| 2012-12-31 | €434.72 Million ≈ $508.24 Million |
+9.88% |
| 2011-12-31 | €395.63 Million ≈ $462.53 Million |
+8.37% |
| 2010-12-31 | €365.07 Million ≈ $426.80 Million |
-7.15% |
| 2009-12-31 | €393.20 Million ≈ $459.69 Million |
+5.80% |
| 2008-12-31 | €371.65 Million ≈ $434.49 Million |
+2.45% |
| 2007-12-31 | €362.76 Million ≈ $424.10 Million |
+114.74% |
| 2006-12-31 | €168.93 Million ≈ $197.50 Million |
+13.87% |
| 2005-12-31 | €148.35 Million ≈ $173.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sartorius Stedim Biotech SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5999.2% over the analyzed period, indicating profitable operations and earnings retention.
Sartorius Stedim Biotech SA Net Assets Breakdown (December 2025)
Sartorius Stedim Biotech SA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.70 Billion | 66.08% |
| Common Stock | €19.50 Million | 0.48% |
| Other Comprehensive Income | €1.37 Billion | 33.45% |
| Total Equity | €4.09 Billion | 100.00% |
Sartorius Stedim Biotech SA Competitors by Market Cap
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telenor ASA
OL:TEL
|
$18.19 Billion |
|
BANCO BRANDESCO SP.ADR 1
F:BREA
|
$18.19 Billion |
|
China Shenhua Energy Company Limited
F:IKF
|
$18.20 Billion |
|
Broadridge Financial Solutions Inc
NYSE:BR
|
$18.21 Billion |
|
Banco de Chile
F:G4RA
|
$18.18 Billion |
|
Amerize Inc.
SW:AMRZ
|
$18.14 Billion |
|
Lennar Corporation
NYSE:LEN
|
$18.12 Billion |
|
China Jushi Co Ltd
SHG:600176
|
$18.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sartorius Stedim Biotech SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,986,600,000 to 4,090,500,000, a change of 103,900,000 (2.6%).
- Net income of 265,600,000 contributed positively to equity growth.
- Dividend payments of 67,099,999 reduced retained earnings.
- New share issuances of 200,000 increased equity.
- Other comprehensive income decreased equity by 103,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €265.60 Million | +6.49% |
| Dividends Paid | €67.10 Million | -1.64% |
| Share Issuances | €200.00K | +0.0% |
| Other Comprehensive Income | €-103.00 Million | -2.52% |
| Other Changes | €8.20 Million | +0.2% |
| Total Change | €- | 2.61% |
Book Value vs Market Value Analysis
This analysis compares Sartorius Stedim Biotech SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 149.48x to 5.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €1.45 | €216.80 | x |
| 2006-12-31 | €1.65 | €216.80 | x |
| 2007-12-31 | €3.54 | €216.80 | x |
| 2008-12-31 | €3.61 | €216.80 | x |
| 2009-12-31 | €3.84 | €216.80 | x |
| 2010-12-31 | €3.77 | €216.80 | x |
| 2011-12-31 | €4.27 | €216.80 | x |
| 2012-12-31 | €4.69 | €216.80 | x |
| 2013-12-31 | €5.19 | €216.80 | x |
| 2014-12-31 | €5.78 | €216.80 | x |
| 2015-12-31 | €6.96 | €216.80 | x |
| 2016-12-31 | €8.22 | €216.80 | x |
| 2017-12-31 | €9.46 | €216.80 | x |
| 2018-12-31 | €11.24 | €216.80 | x |
| 2019-12-31 | €12.57 | €216.80 | x |
| 2020-12-31 | €15.84 | €216.80 | x |
| 2021-12-31 | €17.96 | €216.80 | x |
| 2022-12-31 | €26.58 | €216.80 | x |
| 2023-12-31 | €28.63 | €216.80 | x |
| 2024-12-31 | €41.19 | €216.80 | x |
| 2025-12-31 | €42.04 | €216.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sartorius Stedim Biotech SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.49%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.95%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.96x
- Recent ROE (6.49%) is below the historical average (14.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 14.85% | 4.55% | 1.34x | 2.44x | €7.19 Million |
| 2006 | 17.18% | 5.57% | 1.38x | 2.23x | €12.13 Million |
| 2007 | 1.31% | 1.76% | 0.42x | 1.77x | €-31.53 Million |
| 2008 | 3.54% | 3.56% | 0.56x | 1.76x | €-23.87 Million |
| 2009 | 7.40% | 7.25% | 0.60x | 1.70x | €-10.23 Million |
| 2010 | 10.55% | 8.90% | 0.66x | 1.80x | €2.00 Million |
| 2011 | 10.96% | 9.05% | 0.66x | 1.83x | €3.79 Million |
| 2012 | 13.14% | 10.43% | 0.69x | 1.84x | €13.56 Million |
| 2013 | 13.86% | 11.26% | 0.68x | 1.82x | €18.44 Million |
| 2014 | 13.61% | 10.60% | 0.75x | 1.70x | €19.22 Million |
| 2015 | 18.40% | 13.34% | 0.83x | 1.66x | €53.85 Million |
| 2016 | 20.27% | 14.61% | 0.88x | 1.58x | €77.88 Million |
| 2017 | 18.47% | 14.90% | 0.77x | 1.61x | €73.89 Million |
| 2018 | 20.07% | 17.16% | 0.77x | 1.52x | €104.41 Million |
| 2019 | 20.24% | 16.28% | 0.79x | 1.57x | €118.70 Million |
| 2020 | 23.01% | 17.59% | 0.62x | 2.10x | €189.93 Million |
| 2021 | 25.03% | 14.35% | 0.73x | 2.39x | €248.81 Million |
| 2022 | 35.77% | 25.08% | 0.69x | 2.07x | €631.17 Million |
| 2023 | 11.74% | 11.16% | 0.36x | 2.93x | €45.85 Million |
| 2024 | 4.39% | 6.30% | 0.34x | 2.07x | €-223.56 Million |
| 2025 | 6.49% | 8.95% | 0.37x | 1.96x | €-143.45 Million |
Industry Comparison
This section compares Sartorius Stedim Biotech SA's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,030,188,850
- Average return on equity (ROE) among peers: -46.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sartorius Stedim Biotech SA (DIM) | €4.25 Billion | 14.85% | 0.86x | $18.18 Billion |
| Crossject (ALCJ) | $947.65K | -192.33% | 4.96x | $79.56 Million |
| I.Ceram SA (ALICR) | $6.51 Million | -33.12% | 0.47x | $155.73K |
| Safe Orthopaedics SA (ALSAF) | $-202.35 Million | 0.00% | 0.00x | $127.51K |
| Spineway (ALSPW) | $3.02 Million | -55.79% | 1.97x | $3.74 Million |
| Amplitude Surgical SAS (AMPLI) | $70.91 Million | -20.02% | 2.88x | $299.85 Million |
| EssilorLuxottica S. A. (EL) | $35.33 Billion | 3.05% | 0.49x | $94.74 Billion |
| Bonyf NV (MLBON) | $280.06K | -25.06% | 3.93x | $1.31 Million |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more